Start-up Of Singapore Cancer Diagnostics Received 77 Million Usd Funding

Start-up (start-up) Biotechnology Mirxes Pte in Singapore has mobilized $ 77 million from investors led by CR-CP Life Science funds. CR-CP Life Science is a joint venture between China Resources Group and Thailand Group Charoen Pokphand Group. The company also said that other investors participated in Series C Calls including Rock Springs Capital, Edbi, CCB International Holdings and Keytone Ventures. According to an anonymous source, the capital call has raised the total amount mobilized so far to $ 120 million, bringing this 7-year-old Start-Up $ 500 million.Mirxes will use new capital flows to Speeding up plans to provide non-invasive screening tests, with the target of early detection of 6 common cancers

. Besides, the company will also expand RNA technology globally, serve the research and diagnosis of cardiovascular disease, metabolism and infection. Lihan Zhou Executive Director (39 years) shared in a simulation Problem: "We are building a global business." He also said that in the next 18 months, the company expects to mobilize 200 million USD through personal or publicized calls in Asia or the United States Theo Mr. Zhou, in the next 2 years, Mirxes will recruit Approval of 150 employees, bringing the total number of global employees to 400. Mirxes operate in 3 countries China, Japan and the United States ./. Duy Kien (According to Bloomberg Technology)

. Dịch vụ: Thiết kế website, quảng cáo google, đăng ký website bộ công thương uy tín